Tempest Therapeutics, Inc.
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2017
- $295.0K
- Net income
- -$26.3M
- Total assets
- $16.9M
- Market cap
- $18.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$26.6M
- Income tax
- $0
- Net income
- -$26.3M
- EPS (basic)
- $-6.33
- EPS (diluted)
- $-6.33
Balance sheet
- Total assets
- $16.9M
- Current assets
- $8.3M
- Total liabilities
- $10.3M
- Current liabilities
- $3.3M
- Shareholders’ equity
- $6.7M
Cash flow
- Operating cash flow
- -$26.8M
- Investing cash flow
- $22.6M
- Financing cash flow
- $4.3M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $18.8M
- EPS (diluted)
- $-6.33
- Shares outstanding
- 14.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 28, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $26.3M in FY2017.
- Trading 79% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tempest Therapeutics, Inc..
Write a review
News about Tempest Therapeutics, Inc.
News & sentiment via Polygon.io
